Compare Invesco DB Oil Fund (DBO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs TG Therapeutics Inc — how do they compare? Invesco DB Oil Fund trades at $24.13 (market cap $255.13M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 32× Invesco DB Oil Fund's market cap, and Invesco DB Oil Fund is more actively traded (562,167 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Oil Fund for 31 Days and TG Therapeutics Inc for 16 Days on average.
| DBO | TGTX | |
|---|---|---|
Market Cap | $255.13M | $8.16B |
Volume | 562,167 | 1,735,121 |
Sector | Commodities - Energy | Health |
52-Week High | $26.35 | $59.06 |
52-Week Low | $11.98 | $26.94 |
Typical Hold Time | 31 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBO trades at $24.13, up 2.51% today amid mixed oil market signals. Technical indicators show a neutral overall signal with bearish moving averages, while oscillators remain neutral. Recent news highlights Middle East supply disruptions and OPEC+ production decisions creating volatility in energy markets. The stock faces resistance at $24 and support at $23 levels.
The outlook remains uncertain with geopolitical tensions supporting oil prices but strategic reserve releases creating downward pressure. Key risks include supply chain disruptions and regulatory challenges, while institutional sentiment appears cautious given the mixed technical signals and market volatility.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
